ArticleEJNMMI research2026
Interreader agreement of intraprostatic prostate cancer detection, local extension and staging using [
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03327675 (High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundTo investigate the diagnostic performance and interreader agreement of intraprostatic prostate cancer (PCa) detection, local extension and staging using [18F]PSMA-1007 PET in primary PCa, with whole-mount radical prostatectomy specimens as the reference standard. This prospective study included 66 patients with biopsy-proven PCa who underwent [18F]PSMA-1007 PET/MRI prior to radical prostatectomy. Four nuclear medicine physicians independently evaluated intraprostatic lesions, T stage, extracapsular extension (ECE), seminal vesicle invasion (SVI) and bilaterality, based on PROMISE V2 criteria and a standardized scoring template. Diagnostic accuracy was calculated using whole-mount histopathology as reference. Interreader agreement was assessed using Fleiss’ and weighted kappa statistics.
resultsAccurate lesion-level detection of dominant intraprostatic malignant lesions was achieved across readers with mean sensitivity of 96% (range 96–97%). Mean (range) sensitivity for detecting T3a, T3b, ≥T3, ECE, SVI and bilaterality across readers was 23% (0–50%), 39% (16–53%), 40% (10–63%), 33% (5–59%), 43% (16–58%) and 44% (34–53%), respectively. Mean (range) specificity for detecting T3a, T3b, ≥T3, ECE, SVI and bilaterality across readers was 86% (75–100%), 99% (98–100%), 85% (72–100%), 88% (74–100%), 99% (98–100%) and 86% (71–100%), respectively. Interreader agreement was substantial for bilaterality (kappa 0.66), moderate for SVI (kappa 0.57), fair for T stage (kappa 0.37) and slight for ECE (kappa 0.20).
conclusionAccurate lesion-level detection of [18F]PSMA-1007 PET for dominant intraprostatic malignant lesions can be achieved across multiple readers. However, variable diagnostic performance of [18F]PSMA-1007 PET for local tumor extension was seen between readers, highlighting the need for standardized interpretation guidelines to improve reproducibility and clinical reliability.
trial registrationClinicalTrials.gov, NCT03327675. Registered 10 July 2017, https://clinicaltrials.gov/study/NCT03327675?term=NCT03327675%26rank=1 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.